| |
Tenofovir disoproxil fumarate/emtricitabine fits for all as appropriate
HIV-1 preexposure prophylaxis?
Taramasso L, Riccardi N, Del Puente F,
et al
AIDS Res Hum Retroviruses.
2017 Nov 22
Abstract
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal
Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among
Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse
with Men.
Carballo-Diéguez A, Giguere R, .et al
AIDS Behav. 2017 Nov 8.
Abstract
The role of menopause in tenofovir diphosphate and
emtricitabine triphosphate concentrations in cervical tissue.
Nicol MR, Brewers LM, Kashuba AD, Sykes C.
AIDS. 2017 Nov 2.
Abstract
Plasma Tenofovir-levels to Support Adherence to TDF/FTC
Pre-exposure Prophylaxis for HIV Prevention in MSM in Los Angeles,
California
Landovitz RJ, Beymer M, Kofron R, et al
J Acquir Immune Defic Syndr.
2017 Sep 7
Abstract
Urine tenofovir and emtricitabine concentrations provide biomarker for
exposure to HIV preexposure prophylaxis.
Haaland RE, Martin A, Holder A, et al
AIDS. 2017 Jul
17;31(11):1647-1650.
Abstract
InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir
disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics,
safety and outcomes.
Wang X, Nwokolo N, Korologou-Linden R, et al
HIV Med.
2017 Jun 28.
Abstract
HIV preexposure prophylaxis for adolescents and young adults.
Allen E, Gordon A, Krakower D, Hsu K.
Curr Opin Pediatr.
2017 Jun 8
Abstract
Urine assay for tenofovir to monitor adherence in real time
to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC, Mounzer K, Daughtridge GW, et al
HIV Med. 2017 Apr 26.
Abstract
Bone density, microarchitecture and tissue quality following
long-term treatment with tenofovir/emtricitabine or abacavir/lamivudine.
Güerri-Fernández R, Molina-Morant D,
et al
J Acquir Immune Defic Syndr.
2017 Apr 7.
Abstract
FULL-TEXT ARTICLE
p16<INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine
Metabolite Disposition in HIV-Infected Subjects.
Dumond JB, Collins JW, Cottrell ML,
CPT Pharmacometrics Syst Pharmacol.
2016 Dec 26.
Paper
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological
suppression in HIV-1-infected patients who switch to a
tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D, Di Carlo D, Calcagno A,
et al
J Antimicrob Chemother.
2016 Dec 20
Abstract
Drug interactions between voriconazole, darunavir/ritonavir and
tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus
candidus lung abscess.
Becker A, Sifaoui
F, Gagneux M,
et al
Int J STD AIDS. 2014 Sep 1.
Abstract
Fixed dose combination emtricitabine/tenofovir/efavirenz initiated during
Acute HIV Infection; 96-week efficacy and durability.
Gay CL, Willis SJ, Cope AB, et al
AIDS. 2016 Sep 20
Abstract
Intracellular Tenofovir and Emtricitabine anabolites in Genital, Rectal, and
Blood Compartments from first dose to steady-state.
Seifert S, Chen X, Meditz A, et al
AIDS Res Hum Retroviruses. 2016 Aug 15
Abstract
Exploratory Analysis for the Evaluation of Estimated
Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching
from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to
Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.
Postorino MC, Quiros-Roldan E, Maggiolo F, et al
Open AIDS J. 2016 Jul 15;10:136-43.
Abstract
Drug safety evaluation of oral tenofovir disoproxil
fumarate-emtricitabine for pre-exposure prophylaxis for human
immunodeficiency virus infection.
Trang TP, Dong BJ, Kojima N, Klausner JD.
Expert Opin Drug Saf. 2016 Jul 8.
Abstract
FULL-TEXT ARTICLE
Protocol for an
open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among
people at high risk of HIV infection: the NSW Demonstration Project PRELUDE
Vaccher S, Grulich A, McAllister J, et
al
BMJ Open.
2016 Jun 20;6(6):e012179.
Paper
The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure
Prophylaxis (PrEP) in Individuals With Active Hepatitis B
[No authors listed]
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):e82
Abstract
FULL-TEXT ARTICLE
An Indirect Comparison of Efficacy and Safety of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
M Llibre J, Raffi F, Moyle G, et
al
PLoS One.
2016 May 19;11(5):e0155406.
Paper
Risks and benefits of HIV pre exposure prophylaxis with
tenofovir/emtricitabine in an older man with co-morbidities.
Girometti N, Jones R, Levy J,
et al
AIDS. 2016 May 21
Abstract
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens
in patients with a high viral load.
Flandre P, Pugliese P, Allavena C,
et al
HIV Med.
2016 May;17(5):380-4.
Abstract
Low risk of Proximal Tubular Dysfunction Associated with Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis in Men and Women.
Mugwanya K, Baeten J, Celum C, et al
J Infect Di 2016 Mar 29
Abstract
Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and
Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure
Prophylaxis.
Mugwanya KK, Wyatt C, Celum C,
et al
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374-380.
Abstract
Preexposure tenofovir-emtricitabine reduced HIV infection in men who have
unprotected anal sex with men.
Sacks
HS.
Ann Intern Med. 2016 Jan
19;164(2):JC3.
Abstract
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are
associated with p16INK4a expression in subjects on combination
therapy.
Dumond JB, Francis O, Cottrell M,
et al
Antivir Ther.
2016 Jan 5.
Abstract
|
Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to
a one-tablet regimen may affect patients' perceptions and drug management.
Rotzinger A, Locatelli I, Bugnon O, et al
HIV Med. 2015 Dec 21.
Abstract
Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine
in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults
with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202
clinical trial.
Wilkins E, Fisher M, Brogan AJ, et al
HIV Med. 2015 Dec 9.
Abstract
The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation
more than 1.5 mg/dL among the Patients Treated with
Tenofovir/Emtricitabine-containing HAART Regimens.
Jin S, Kim MH, Park JH, et al
Infect Chemother. 2015
Dec;47(4):239-46
Abstract
Changes in Serum Markers of Inflammation and Endothelial Activation in
HIV-Infected Antiretroviral Naive Patients Starting A Treatment with
Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L, Magistrelli E, Danese I,
et al
Curr HIV Res.
2016;14(1):61-70.
Abstract
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine after
Directly Observed Dosing in Healthy Volunteers to establish Adherence Benchmarks
(HPTN 066).
Hendrix
CW, Andrade A, Bumpus NN, et al
AIDS Res Hum Retroviruses. 2015
Sep 28.
Abstract
How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines
Prevention and Pleasure: A Call to Destigmatize "Truvada Whores".
Calabrese SK, Underhill K.
Am J Public Health. 2015 Aug 13:
Abstract
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment
With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir,
Darunavir/Ritonavir, or Raltegravir.
Brown TT, Moser C, Currier JS, et al
J Infect Dis. 2015 May 5
Abstract
Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral
Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.
Rudy BJ, Kapogiannis BG, Worrell C, et al
J Acquir Immune Defic Syndr. 2015 May 1;69(1):52-60.
Abstract
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative
Persons in a Randomized, Double-Blind, Placebo-Controlled Trial: DXA Results
from iPrEx.
Mulligan K, Glidden DV, Anderson PL, et al
Clin Infect Dis. 2015 Apr 23.
Abstract
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, cross-over,
double-blind, placebo-controlled trial.
Santos JR, Saumoy M, Curran A, et al
Clin Infect Dis. 2015 Apr
13.
Abstract
The Science of Being a Study Participant: FEM-PrEP Participants'
Explanations for Overreporting Adherence to the Study Pills and for the
Whereabouts of Unused Pills.
Corneli AL, McKenna K, Perry B, et al.
J Acquir Immune Defic Syndr. 2015 Apr
15;68(5):578-584.
Abstract
Renal safety of coformulated tenofovir/emtricitabine vs other
nucleoside analogues in combination therapy in antiretroviral-naive patients
aged 50 years or older in Spain: The TRIP study.
Pedrol E, Caro-Murillo AM, et al
HIV Clin Trials. 2015
Jan-Feb;16(1):43-8.
Abstract
Changes in Glomerular Kidney Function Among HIV-1-Uninfected Men
and Women Receiving Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure
Prophylaxis: A Randomized Clinical Trial.
Mugwanya KK, Wyatt C, Celum C, at al
JAMA
Intern Med. 2014 Dec 22
Abstract
Evaluation of Rapidly Disintegrating Vaginal Tablets of
Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention.
Clark MR, Peet MM, Davis S, et al
Pharmaceutics. 2014 Dec 8;6(4):616-631.
Abstract
Dose-response for Starting and Stopping HIV Pre-Exposure
Prophylaxis (PrEP) for MSM.
Seifert SM, Glidden DV, Meditz AL, et al
Clin Infect Dis. 2014 Nov 18.
Abstract
Lower prevalence of drug resistance mutations at first-line
virological failure to first-line therapy with atripla vs.
tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple
tablet therapy.
Blanco JL, Montaner JS,
Marconi VC, et al
AIDS.
2014 Nov 13;28(17):2531-9.
Abstract
Single-agent tenofovir versus combination emtricitabine plus
tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data
from a randomised, double-blind, phase 3 trial.
Baeten JM, Donnell D, Mugo NR, et al
Lancet Infect Dis.
2014 Oct 8
Abstract
Changes in proteinuria and albuminuria with initiation of antiretroviral
therapy: data from a randomized trial comparing tenofovir disoproxil
fumarate/emtricitabine versus abacavir/lamivudine.
Wyatt CM, Kitch D, Gupta SK, et al
J Acquir Immune Defic Syndr.
2014 Sep 1;67(1):36-44
Abstract
The Combined Anti-HIV-1 Activity of Emtricitabine and Tenofovir
with the Integrase Inhibitors Elvitegravir or Raltegravir Show High Levels of
Synergy In Vitro.
Kulkarni R, Hluhanich R, McColl DM, et al
Antimicrob Agents Chemother. 2014 Aug 4.
Abstract
Daily Oral Tenofovir and Emtricitabine-Tenofovir Preexposure
Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual
HIV-1-Uninfected Men and Women: A Subgroup Analysis of a Randomized Trial.
Celum C, Morrow RA, Donnell D, et al
Ann Intern Med. 2014 Jul 1;161(1):11-19.
Abstract
A 48-week study of fat molecular alterations in HIV naïve patients starting
tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Domingo P, Gutierrez MD, Gallego-Escuredo JM,
et
al
J Acquir Immune Defic Syndr.
2014 May 12
Abstract
HIV-1 Drug Resistance in the iPrEx
Pre-Exposure Prophylaxis Trial.
Liegler T, Abdel-Mohsen M, Bentley LG, et al
J Infect Dis.
2014 Apr 16.
Abstract
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with
tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for
96 weeks: The CASTLE biomarker substudy.
Moyle G, Hardy H, Uy J,
et al
Antivir Ther.
2014 Apr 16.
Abstract
Delayed onset renal failure in a patient on tenofovir based antiretroviral
regimen.
Krishna MM, Subbalaxmi MV, Uppin M, Radhika S.
Indian J Pharmacol. 2014
Mar;46(2):230
Abstract
-FULL-TEXT ARTICLE
Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised
Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in
Botswana.
Kasonde M, Niska RW, Rose C, et al
PLoS One. 2014 Mar
13;9(3):e90111.
Paper
Tenofovir, Emtricitabine, and Darunavir/Ritonavir Pharmacokinetics in an
HIV-Infected Patient After Roux-en-Y Gastric Bypass Surgery
Macbrayne CE, Blum JD, Kiser JJ.
Ann Pharmacother. 2014 Mar 10.
Abstract
Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of
Inflammatory Markers More Than Antiretroviral Drugs Alone
in Antiretroviral Therapy-Naive HIV-Infected Patients.
Calza L, Vanino E, Salvadori C, et al
HIV Clin Trials. 2014
Jan-Feb;15(1):1-13.
Abstract
Changes in renal function associated with oral emtricitabine/tenofovir
disoproxil fumarate use for HIV pre-exposure prophylaxis.
Solomon MM, Lama JR, Glidden DV, et al
AIDS. 2014 Feb 4.
Abstract
FULL-TEXT
ARTICLE
No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV
Preexposure Prophylaxis.
Marcus JL, Glidden DV, Mayer KH, et al
PLoS One. 2013 Dec 18;8(12):e81997.
Paper
FULL TEXT ARTICLE
Neurological
syndrome in an HIV-prevention trial participant randomized to daily tenofovir
disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya
Owino F, Mandala J, Ambia J,
et al
Int Med Case Rep J.
2013 Nov 29;6:91-
Paper
Safety, Efficacy, and Persistence of Emtricitabine/Tenofovir Versus
Other Nucleoside Analogues in Naive Subjects Aged 50 Years or Older in
Spain: The TRIP Study.
Blanco JR, Caro-Murillo AM, Castaño MA, et al
HIV Clin Trials.
2013 Sep-Oct;14(5):204-15.
Abstract
Efficacy and tolerability of antiretroviral therapy containing tenofovir
disoproxil fumarate-emtricitabine-efavirenz in treatment-naive patients
infected with HIV-1 in Bobo Dioulasso (Burkina Faso, 2009-2011).
Zoungrana J, Hema A, Bado G, et
al
Bull Soc Pathol Exot.
2013 Oct 16.
Abstract
Pre-exposure prophylaxis for the prevention of sexual HIV transmission;
new preventative strategy using tenofovir/emtricitabine.
Boot J, Rump BO, Boucher CA,
et al
Ned Tijdschr Geneeskd.
2013;157(27):A6063
Abstract
Neutrophil gelatinase-associated lipocalin, a marker of tubular
dysfunction, is not increased in long-term virologically controlled
patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Allavena C, Bach-Ngohou K, Billaud E, et al
J Antimicrob Chemother.
2013 Jun 30
Abstract
Early upper digestive tract side effects of zidovudine with tenofovir plus
emtricitabine in West African adults with high CD4 counts.
Ouattara E, Danel C, Moh R, Gabillard
D, et al
J Int AIDS Soc. 2013
Apr 30;16:
Abstract
Once-daily darunavir/ritonavir and abacavir/lamivudine
versus tenofovir/emtricitabine for treatment-naïve patients with a
baseline viral load of more than 100 000 copies/ml.
Nishijima T, Komatsu H, Teruya K, et al
AIDS.
2013 Mar 13;27(5):839-42
Abstract
Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of
its Use in HIV-1 Pre-Exposure Prophylaxis.
Plosker GL.
Drugs. 2013 Feb 27
Abstract
Pharmacokinetics of two common antiretroviral regimens in
older HIV-infected patients: a pilot study.
Dumond J, Adams
J, Prince H, et al
HIV Med. 2013 Feb 24
Abstract
SWIFT: Prospective 48 Week Study to Evaluate Efficacy and Safety
of Switching to Emtricitibine/Tenofovir from Lamivudine/Abacavir in
Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor
Containing Antiretroviral Regimen.
Campo R, Dejesus E, Bredeek UF, et al
Clin Infect Dis. 2013 Jan
29.
Abstract |
Tenofovir, emtricitabine intracellular and plasma, and efavirenz
plasma concentration decay following drug intake cessation: implications for HIV
treatment and prevention.
Jackson A, Moyle G, Watson V, et
al
J Acquir Immune Defic Syndr. 2012 Dec 28
Abstract
FULL TEXT ARTICLE
Prevention of Vaginal SHIV Transmission in Macaques by a Coitally-Dependent
Truvada Regimen.
Radzio J, Aung W, Holder A, et al
PLoS One.
2012;7(12):e50632.
Paper
Indirect treatment comparison of efficacy, safety and resistance
of EVG/COBI/FTC/TDF (Quad) vs. RAL+FTC/TDF in treatment-naïve HIV patients.
Dejesus E, Felix J, Vandewalle B, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18239.
Abstract
Impact of emtricitabine/tenofovir (FTC/TDF) on renal function in
antiretroviral-naïve patients≥50 years - TRIP study.
Blanco J, Castaño M, Olalla J, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18312.
Abstract
STRike - characteristics of HIV-1-infected patients treated with
a single-tablet regimen in daily clinical practice.
Esser S, Heiken H, Gallo L, et al
J Int AIDS
Soc. 2012 Nov 11;15(6):18356
Abstract
Effectiveness and safety of a single-tablet regimen of
emtricitabine/efavirenz/tenofovir in HIV-1-infected patients in infectious
diseases department.
Xerinda S, Neves N, Santos S,
J Int AIDS Soc. 2012
Nov 11;15(6):18383.
Abstract
A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted
atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r
vs. RAL BID + ATV BID.
Cohen C, Green J, Olivet H,
et alJ
Int AIDS Soc. 2012 Nov 11;15(6):18279.
Abstract
Changes in Fat Mitochondrial DNA and Function in Subjects
Randomized to Abacavir/Lamivudine or Tenofovir DF/Emtricitabine with
Atazanavir/Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s,
substudy of A5202.
McComsey GA, Daar ES,
O'Riordan , et al
J
Infect Dis. 2012 Nov 29.
Abstract
Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in
Blood Cells Compared with Isolated
Peripheral Blood Mononuclear Cells: A New Measure of Antiretroviral
Adherence?
Adams JL, Sykes C, Menezes
P,
et al
J Acquir Immune Defic Syndr.
2012 Oct 29.
Abstract |
Incidence of renal toxicity in HIV-infected,
antiretroviral-naïve patients starting tenofovir/emtricitabine
associated
with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L, Trapani F, Salvadori C,
et al
Scand J Infect Dis.
2012 Sep 19.
Abstract
Emtricitabine-Tenofovir Concentrations and Pre-Exposure
Prophylaxis Efficacy in Men Who Have Sex with Men.
Anderson PL, Glidden
DV, Liu A et al.
Sci
Transl Med. 2012 Sep 12;4(151):
Abstract
Oral antiretroviral chemoprophylaxis: current status.
Baeten J, Celum C.
Curr Opin HIV AIDS.
2012 Sep 7
Abstract
Emtricitabine/tenofovir in the treatment of HIV infection:
current PK/PD evaluation.
Uglietti A, Zanaboni D, Gnarini
M, Maserati R.
Expert Opin Drug Metab Toxicol.
2012 Sep
Abstract |
Tenofovir, emtricitabine, and tenofovir-diphosphate in dried
blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla J, Zheng JH, Rower
JE, et al
AIDS Res Hum Retroviruses. 2012 Aug 31.
Abstract
Duration of first-line antiretroviral therapy with tenofovir and
emtricitabine combined with atazanavir/ritonavir, efavirenz
or
lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A, Prinapori R,
Giannarelli D, et al
J Antimicrob Chemother. 2012 Aug 21
Abstract |
Switching to tenofovir/emtricitabine from abacavir/lamivudine in
HIV-infected adults with raised cholesterol: effect on lipid profiles.
Behrens G, Maserati R, Rieger A
Antivir Ther. 2012 Aug 15
Abstract
Double Oral Administration of Emtricitabine/Tenofovir Prior to Virus Exposure
Protects against Highly Pathogenic
Simian/Human Immunodeficiency Virus Infection in Macaques.
Nakasone T, Murakami
T, Yamamoto N.
Jpn J Infect Dis. 2012 Jul;65(4):345-9.
Abstract
A randomized comparison of second-line lopinavir/ritonavir monotherapy vs.
tenofovir/lamivudine/lopinavir/ritonavir i
n patients failing NNRTI-regimens: the
HIV STAR study.
Bunupuradah T, Chetchotisakd P, Ananworanich J, et al
Antivir Ther. 2012 Jul 2.
Abstract |
FULL-TEXT
DOCUMENT
FDA Approves Truvada for reducing the risk of sexually acquired HIV infection
USFDA
July 16,2012
Internet Document
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.
Baeten JM, Donnell D, Ndase P, Mugo NR, et al
N Engl J Med.
2012 Jul 11.
.
Abstract
FULL-TEXT ARTICLE
Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing
Treatment to Tenofovir-Emtricitabine or
Abacavir-Lamivudine.
Haskelberg H, Hoy
JF, Amin J, et al
PLoS One. 2012;7(6):e38377
Paper |
WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine +
efavirenz for patients with HIV.
Omeje I, Okwundu CI.
Cochrane Database Syst Rev.
2012 May 16;5:CD007276.
Abstract
The effect of efavirenz versus nevirapine-containing regimens on immunologic,
virologic and clinical outcomes
in a prospective observational study.
The HIV-CAUSAL Collaboration.
AIDS. 2012 Apr 26.
Abstract
Changes in body
composition and mitochondrial DNA in HIV-1-infected patients switching
to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a
substudy of the BICOMBO Trial.
Curran A, Martinez E, Podzamczer D, et al
Antivir Ther.
2012 Feb 28.
Abstract |
FDA
Grants Priority Review for Truvada® for Reducing the Risk of Acquiring HIV
Infection
Gilead Sciences Press Release
Feb. 13, 2012
News Release
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for
Prevention of HIV-1 Transmission.
Patterson KB, Prince HA, Kraft E,
et al
Sci Transl Med. 2011
Dec 7;3(112):112re4
Abstract
FULL-TEXT
ARTICLE
Predictors of Limb Fat Gain in HIV Positive Patients Following a
Change to Tenofovir-Emtricitabine or
Abacavir-Lamivudine.
Martin A, Amin J, Emery S,
et al
PLoS One.
2011;6(10):e26885
Paper |
A randomized, pilot trial to evaluate glomerular filtration rate by
creatinine or cystatin C in naïve
HIV-infected patients after tenofovir/emtricitabine in combination
with atazanavir/ritonavir or efavirenz.
Albini L, Cesana BM, Motta D, et al
J Acquir Immune Defic Syndr.
2011 Oct 11
Abstract
Once-daily antiretroviral therapy among
treatment-experienced Muslim patients fasting for the month of
Ramadan.
Yakasai AM, Muhammad H, Babashani M,
et al
Trop Doct. 2011 Sep 13
Abstract
Abacavir/Lamivudine Versus Tenofovir
DF/Emtricitabine as Part of Combination Regimens for Initial
Treatment of HIV:
Final Results.
Sax PE,
Tierney C, Collier AC, et al
J Infect Dis. 2011
Oct;204(8):1191-1201.
Abstract
Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine
Among Treatment-Naive
HIV-Infected Patients Initiating Therapy.
Tan DH, Chan K, Raboud J, et al
J Acquir Immune Defic Syndr.
2011 Sep 1;58(1):38-46.
Abstract
Randomized comparison of renal effects, efficacy, and safety with
once-daily abacavir/lamivudine versus
tenofovir/emtricitabine, administered with efavirenz, in
antiretroviral-naive, HIV-1-infected adults: 48-week
results from the ASSERT study.
Post FA, Moyle GJ, Stellbrink HJ, et al
J Acquir Immune Defic Syndr.
2010 Sep;55(1):49-57.
Abstract
Prevalence of low-level HIV-1 variants with reverse transcriptase
mutation K65R and the effect of antiretroviral
drug exposure on variant levels.
Kozal MJ,
Chiarella J, St John EP,
et al
Antivir Ther. 2011;16(6):925-9.
Abstract
Comparison of abacavir/lamivudine and
tenofovir/emtricitabine among treatment-naïve
HIV-infected patients initiating therapy.
Tan DH,
Chan K, Raboud J, Cooper C, et al
J Acquir Immune Defic Syndr.
2011 Jun 24.
Abstract
Peripheral and Central Fat Changes in Subjects Randomized to
Abacavir-Lamivudine or Tenofovir-Emtricitabine
With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s.
McComsey GA, Kitch D,
Sax PE,
et al
Clin Infect Dis.
2011 Jul;53(2):185-96.
Abstract
Protection against Rectal Transmission of an
Emtricitabine (FTC)-Resistant SHIV162p3M184V
Mutant by Intermittent Prophylaxis with Truvada.
Cong ME, Youngpairoj AS,
Zheng Q, et al
J Virol. 2011 Jun 1.
Abstract
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons
Randomized to Receive
Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine
Along With Efavirenz or
Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of
ACTG A5202.
McComsey GA, Kitch D, Daar ES,
et
al
J Infect Dis.
2011 Jun;203(12):1791-801.
Abstract
Beliefs about antiretroviral therapy, treatment adherence and quality
of life in a 48-week randomised
study of continuation of zidovudine/lamivudine or switch to tenofovir
DF/emtricitabine, each with efavirenz.
Cooper V, Moyle GJ, Fisher M,
et al
AIDS Care.
2011 Apr 5:1-9.
Abstract
Pharmacological considerations for tenofovir and
emtricitabine to prevent HIV infection.
Anderson PL, Kiser JJ, Gardner EM,
et al
J Antimicrob Chemother.
2010 Nov 30.
Abstract |
Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil
Fumarate
Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label,
Prospective Study.
Huang F, Scholl P, Huang DB,
et al
Basic Clin Pharmacol Toxicol.
2010 Oct 27.
Abstract |
Tolerability of HIV postexposure prophylaxis with
tenofovir/emtricitabine and
lopinavir/ritonavir tablet formulation.
Tosini W, Muller P,
Prazuck T, et al
AIDS. 2010 Aug 19
Abstract |
Pharmacokinetics and Bioavailability of an Integrase and Novel
Pharmacoenhancer-
Containing Single-Tablet Fixed-Dose Combination Regimen for the
Treatment of HIV.
German P, Warren D, West S, Hui J, Kearney BP.
J Acquir Immune Defic Syndr.
2010 Jul 30.
Abstract |
Randomized Comparison of Renal Effects, Efficacy, and Safety With
Once-Daily
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With
Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From
the ASSERT
Study.
Post FA, Moyle GJ, Stellbrink HJ, et al
J Acquir Immune Defic Syndr. 2010 Apr 24
Abstract |
Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted
Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine
in Antiretroviral-Naive HIV-Infected Patients.
Ross LL, Weinberg WG, Dejesus E, et al
AIDS Res Hum Retroviruses.
2010 Apr 9
Abstract |
Does choice of combination antiretroviral therapy (cART) alter changes in
cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected
individuals commencing cART? A randomized, controlled study.
Winston A, Duncombe C, Li PC, et al
Clin Infect Dis.
2010 Mar 15;50(6):920-9.
Abstract |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine
in HIV-infected patients.
Labarga P, Medrano J,
Seclen E,
et al
AIDS. 2010 Feb 15.
Abstract |
Emerging mutations at virological failure of HAART combinations containing
tenofovir and lamivudine or emtricitabine.
Maserati R, De Silvestri A, Uglietti A, et al
AIDS. 2010 Jan 30.
Abstract |
Switching the nucleoside reverse transcriptase
inhibitor backbone to
reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate +
emtricitabine promptly improves triglycerides and low-density lipoprotein
cholesterol in dyslipidaemic patients.
Valantin MA, Bittar R, de Truchis P,
et al
J Antimicrob Chemother. 2010 Jan 6
Abstract
|
Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir
and Emtricitabine
plus Twice-Daily Nevirapine.
Amoroso A, Gilliam BL, Talwani R,
et al
HIV Clin Trials.
2009 Sep-Oct;10(5):320-3.
Abstract |
Lower limb high arterial flow induced by tenofovir and
emtricitabine treatment.
Periard D, Yerly P, Hayoz D,
et al
Antivir Ther.
2009;14(6):865-7.
Abstract |
Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal:
A 96-Week Pilot Trial in
Treatment-Naive Patients.
Landman R, Poupard M, Diallo M, et al
J Int Assoc Physicians AIDS Care
2009 Sep 15.
Abstract |
Complete Protection from Repeated Vaginal SHIV Exposures in Macaques
by a
Topical Gel Containing Tenofovir Alone or with Emtricitabine.
Parikh UM, Dobard C, Sharma S, et al
J Virol. 2009 Aug 5.
Abstract |
Development of HIV-1 Drug Resistance Through 144 Weeks in
Antiretroviral-
Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and
Efavirenz
Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934.
Margot NA, Enejosa J, Cheng AK, et al
J Acquir Immune Defic Syndr.
2009 Jul 29
Abstract |
A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or
Replacement
With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated
HIV-1-Infected
Individuals.
Fisher M, Moyle GJ, Shahmanesh M,
et al
J Acquir Immune Defic Syndr.
2009 Jun 25
Abstract |
Randomized, double-blind, placebo-matched, multicenter trial of
abacavir/lamivudine or
tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV
treatment.
Smith KY, Patel P, Fine D, et al
AIDS. 2009 Jun 17.
Abstract |
Switch from a ZDV/3TC-based Regimen to a Completely
Once Daily (QD) Regimen of
Emtricitabine/Tenofovir DF Fixed Dose
Combination plus a Third QD Agent (sonett).
Arasteh K, Weitner L, Fenske S, et al
Eur J Med Res. 2009
May 14;14(5):195-9.
Abstract |
Emtricitabine/Tenofovir Disoproxil Fumarate: In Combination with
a Protease Inhibitor in HIV-1 Infection.
Perry CM.
Drugs.
2009;69(7):843-57.
Abstract |
A Simplification Trial Switching From Nucleoside Reverse Transcriptase
Inhibitors to Once-Daily
Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in
HIV-1-Infected Patients With Virological
Suppression.
Martínez E, Arranz JA, Podzamczer D,
et al
J Acquir Immune Defic Syndr.
2009 Apr 24.
Abstract |
Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro
Modulation of ABC transporter and
Intracellular Drug Accumulation.
Bousquet L, Pruvost A, Guyot AC, et al
Antimicrob Agents Chemother. 2008
Dec 15
Abstract |
Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus
at steady state
when administered alone or in combination.
Chittick GE, Zong J, Begley JA,. et al
Int J Clin Pharmacol Ther.
2008 Dec;46(12):627-36
Abstract
|
|
General
Reports
Truvada Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
